Pulse Biosciences (PLSE) reports 86% thyroid nodule response, but can the results hold?
Pulse Biosciences reports an 86% thyroid nodule response in PRECISE-BTN. See what the interim data mean for clinical adoption.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
BostonGene AI framework identifies actionable targets in 65% of cancer of unknown primary cases at USCAP 2026
BostonGene presents multimodal AI CUP framework at USCAP 2026, identifying actionable targets in 65%+ of patients. Read the analysis.